Inhibrx Biosciences Inc (INBX)
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapies for people with serious and life-threatening diseases. The company’s pipeline includes INBRX-109, a phase 1 tetravalent candidate designed to target death receptor 5 for unresectable or metastatic conventional chondrosarcoma, as well as INBRX-106, a hexavalent sdAb-based candidate targeting OX4 for multiple solid tumor indications, including non-small cell lung cancer, melanoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Incorporated in 2024, the company is based in La Jolla, California. Its common stock is listed on NASDAQ under the symbol INBX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INBX
|
$53.86
|
-37.2% Downside
|
Overvalued
|
$277.50
|
223.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-9.7x
|
-59.9x
|
969.9x
|
1.234 B
|
1.28 B
|
12.8%
|
57.0%
|
0.2
|
—
|
101.3%
|
